The Children?s Oncology Group (COG) is the pediatric clinical trials group of the National Clinical Trials Network (NCTN). Over 90% of United States and Canadian children and adolescents with cancer are treated at COG institutions with no racial, ethnic or geographic bias to registration, allowing for near- population-based clinical, translational and basic research. COG has established a strong track record of collecting and banking tumor and non-diseased biospecimens from patients enrolled in COG-sponsored clinical trials, most of which include randomized treatment questions. The COG Biospecimen Bank (COG Biobank), located within the Biopathology Center (part of the Abigail Wexner Research Institute at Nationwide Children?s Hospital), aims to provide high-quality pediatric and adolescent human malignant biospecimens to the research community. Upon review and approval, biospecimens are prioritized for distribution to the COG investigators defined in the clinical trial protocols. After the needs of the planned research have been addressed, residual (legacy) banked biospecimens can be distributed to other investigators within and outside COG via the NCTN Navigator The COG Group and Biobank Concierges can also facilitate access to COG legacy biospecimens that are not currently uploaded in Navigator. For all biospecimen distribution projects, a feasibility assessment by the COG Biobank and the COG Statistical and Data Management Center (SDMC) is completed prior to proposal submission. This proposal supports the collection, processing, and distribution of biospecimens from patient enrolled on COG-sponsored trials. The Pediatric Division of the Cooperative Human Tissue Network (CHTN) then facilitates the distribution of the approved legacy biospecimens. The COG Biobank seeks to directly promote and support outstanding research in the diagnosis and treatment of pediatric cancer through centralized collection, quality control, storage, and distribution procedures. The COG Biobank will continue efforts to provide the latest biorepository-based technological innovations and best practices, resulting in constant improvements in our operational capabilities, investigator access to biospecimens, investigator satisfaction, and the stewardship of these precious resources. Under proper regulatory guidelines and in association with the COG SDMC, the COG Biobank will support translational aspects of cutting-edge research by ensuring appropriate tracking of biospecimens as well as linkage to existing demographic, clinical, biological, treatment, and outcome data. Finally, the COG Biobank will provide investigators with a comprehensive database solution and dynamic informatics tools that facilitate pediatric cancer research. The COG Biobank also plans to support the processing, banking, and distribution of biospecimens to the Cancer Immune Monitoring and Analysis Centers (CIMACs).
Cure rates for pediatric cancer have improved significantly over the past 30 years due to the enrollment of nearly all affected children in the United States on Children's Oncology Group (COG) clinical trials, and the research completed using biospecimens banked from these studies. The COG Biospecimen Bank aims to support additional pediatric and adolescent cancer research by collecting, processing, and distributing high quality biospecimens.
|Ooms, Ariadne H A G; Gadd, Samantha; Gerhard, Daniela S et al. (2016) Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clin Cancer Res 22:5582-5591|
|Keller, James; Nimnual, Anjaruwee S; Varghese, Mathew S et al. (2016) A Novel EGFR Extracellular Domain Mutant, EGFR?768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma. Mol Cancer Res 14:740-52|
|Temple, William; Mendelsohn, Lori; Kim, Grace E et al. (2016) Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging 43:474-481|
|Matloub, Yousif; Stork, Linda; Asselin, Barbara et al. (2016) Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies. Pediatr Blood Cancer 63:255-61|
|Iacobucci, Ilaria; Li, Yongjin; Roberts, Kathryn G et al. (2016) Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell 29:186-200|
|Glover, Jason; Krailo, Mark; Tello, Tanya et al. (2015) A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. Pediatr Blood Cancer 62:450-5|
|Auer, H; Mobley, J A; Ayers, L W et al. (2014) The effects of frozen tissue storage conditions on the integrity of RNA and protein. Biotech Histochem 89:518-28|
|Kang, Guolian; Bi, Wenjian; Zhao, Yanlong et al. (2014) A new system identification approach to identify genetic variants in sequencing studies for a binary phenotype. Hum Hered 78:104-16|
|Walter, Roland B; Laszlo, George S; Alonzo, Todd A et al. (2013) Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. Am J Hematol 88:694-702|
|Holmfeldt, Linda; Wei, Lei; Diaz-Flores, Ernesto et al. (2013) The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45:242-52|
Showing the most recent 10 out of 13 publications